Literature DB >> 24736340

The deadly impact of extreme drug resistance in Acinetobacter baumannii.

Brad Spellberg1, Robert A Bonomo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24736340      PMCID： PMC4184139          DOI： 10.1097/CCM.0000000000000181

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  24 in total

1.  Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia.

Authors:  Ki Tae Kwon; Won Sup Oh; Jae-Hoon Song; Hyun-Ha Chang; Sook-In Jung; Shin-Woo Kim; Seong Yeol Ryu; Sang Taek Heo; Dong Sik Jung; Ji-Young Rhee; Sang Yop Shin; Kwan Soo Ko; Kyong Ran Peck; Nam Yong Lee
Journal:  J Antimicrob Chemother       Date:  2007-01-09       Impact factor: 5.790

Review 2.  Clinical impact and pathogenicity of Acinetobacter.

Authors:  M-L Joly-Guillou
Journal:  Clin Microbiol Infect       Date:  2005-11       Impact factor: 8.067

Review 3.  Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings.

Authors:  P A Tilley; F J Roberts
Journal:  Clin Infect Dis       Date:  1994-06       Impact factor: 9.079

4.  Validation of partial rpoB gene sequence analysis for the identification of clinically important and emerging Acinetobacter species.

Authors:  Vijay A K B Gundi; Lenie Dijkshoorn; Sophie Burignat; Didier Raoult; Bernard La Scola
Journal:  Microbiology       Date:  2009-04-23       Impact factor: 2.777

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 6.  Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality.

Authors:  H Seifert; A Strate; G Pulverer
Journal:  Medicine (Baltimore)       Date:  1995-11       Impact factor: 1.889

7.  Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies.

Authors:  R H Glew; R C Moellering; L J Kunz
Journal:  Medicine (Baltimore)       Date:  1977-03       Impact factor: 1.889

8.  Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections.

Authors:  Ayşe Erbay; Aysun Idil; M Gökhan Gözel; Ipek Mumcuoğlu; Neriman Balaban
Journal:  Int J Antimicrob Agents       Date:  2009-09-08       Impact factor: 5.283

Review 9.  Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis.

Authors:  E V Lemos; F P de la Hoz; T R Einarson; W F McGhan; E Quevedo; C Castañeda; K Kawai
Journal:  Clin Microbiol Infect       Date:  2013-10-17       Impact factor: 8.067

10.  Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea.

Authors:  Young Kyoung Park; Kyong Ran Peck; Hae Suk Cheong; Doo Ryeon Chung; Jae Hoon Song; Kwan Soo Ko
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883
View more
  24 in total

1.  The role of conserved surface hydrophobic residues in the carbapenemase activity of the class D β-lactamases.

Authors:  Marta Toth; Clyde A Smith; Nuno T Antunes; Nichole K Stewart; Lauren Maltz; Sergei B Vakulenko
Journal:  Acta Crystallogr D Struct Biol       Date:  2017-07-28       Impact factor: 7.652

2.  Crystal structure of 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase from the ESKAPE pathogen Acinetobacter baumannii.

Authors:  Kristin A Sutton; Jennifer Breen; Thomas A Russo; L Wayne Schultz; Timothy C Umland
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-02-16       Impact factor: 1.056

3.  If antibiotics did not exist.

Authors:  Marin H Kollef; Cristina Vazquez Guillamet
Journal:  Intensive Care Med       Date:  2014-11-11       Impact factor: 17.440

Review 4.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.

Authors:  Bartolome Moya; Isabel M Barcelo; Sachin Bhagwat; Mahesh Patel; German Bou; Krisztina M Papp-Wallace; Robert A Bonomo; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Light Modulates Metabolic Pathways and Other Novel Physiological Traits in the Human Pathogen Acinetobacter baumannii.

Authors:  Gabriela L Müller; Marisel Tuttobene; Matías Altilio; Maitena Martínez Amezaga; Meaghan Nguyen; Pamela Cribb; Larisa E Cybulski; María Soledad Ramírez; Silvia Altabe; María Alejandra Mussi
Journal:  J Bacteriol       Date:  2017-04-25       Impact factor: 3.490

7.  Toward a structome of Acinetobacter baumannii drug targets.

Authors:  Logan M Tillery; Kayleigh F Barrett; David M Dranow; Justin Craig; Roger Shek; Ian Chun; Lynn K Barrett; Isabelle Q Phan; Sandhya Subramanian; Jan Abendroth; Donald D Lorimer; Thomas E Edwards; Wesley C Van Voorhis
Journal:  Protein Sci       Date:  2020-01-20       Impact factor: 6.725

8.  Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury.

Authors:  Todd A Miano; Ebbing Lautenbach; F Perry Wilson; Wensheng Guo; Yuliya Borovskiy; Sean Hennessy
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-15       Impact factor: 8.237

9.  In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Kirk Nelson; Debora Rubio-Aparicio; Ruslan Tsivkovski; Dongxu Sun; Maxim Totrov; Michael Dudley; Olga Lomovskaya
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections.

Authors:  Maria Helena Rigatto; Fabiane J Vieira; Laura C Antochevis; Tainá F Behle; Natane T Lopes; Alexandre P Zavascki
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.